Discover and read the best of Twitter Threads about #Bebtelovimab
Most recents (6)
Status of the latest #COVID19 Wave in #NewYork #BellwetherState
NY just uploaded 425 sequences - had to update charts!
Top circulating variants - BA.5.2.1 (20%), BA.4.6 (15%)
Proportion of BQ* lineages are increasing
BQ.1* (2.84%) & BQ.1.1* (1.00%)👀
NY just uploaded 425 sequences - had to update charts!
Top circulating variants - BA.5.2.1 (20%), BA.4.6 (15%)
Proportion of BQ* lineages are increasing
BQ.1* (2.84%) & BQ.1.1* (1.00%)👀
BQ.1.1 (aka #Cerberus) is able to evade all available mAb therapeutics including #Evusheld and #Bebtelovimab.
Bivalent boosters (OG/Omicron.BA.5) will potentially protect the boosted from getting severe disease.
Please get #boosted ASAP!
Bivalent boosters (OG/Omicron.BA.5) will potentially protect the boosted from getting severe disease.
Please get #boosted ASAP!
We may have to switch to #SequenceToTreat from #TestToTreat soon...
mAbs work well against BA.2.3.20
#Bebtelovimab works well against most BA.2.75* without spike K444 mutations
None of the mAb currently authorized by @US_FDA will work against BQ.1. lineage
mAbs work well against BA.2.3.20
#Bebtelovimab works well against most BA.2.75* without spike K444 mutations
None of the mAb currently authorized by @US_FDA will work against BQ.1. lineage
Lineages to watch
1. BQ.1*
2. BQ1.1*
3. BA.2.75.2*
4. XBB - Recombinant of BJ.1 and BM.1.1.1
5. BA.2.3.20
All lineages have appreciable ACE2 affinity;
1-4 are highly immune evasive;
1 & 2 evade many therapeutics - #Evusheld and #Bebtelovimab
fortune.com/well/2022/09/2…
1. BQ.1*
2. BQ1.1*
3. BA.2.75.2*
4. XBB - Recombinant of BJ.1 and BM.1.1.1
5. BA.2.3.20
All lineages have appreciable ACE2 affinity;
1-4 are highly immune evasive;
1 & 2 evade many therapeutics - #Evusheld and #Bebtelovimab
fortune.com/well/2022/09/2…
Credits to Lineage Spotters/Proposers
BA.2.3.20 - @LongDesertTrain
BQ.1*/BQ.1.1* - @siamosolocani
BA.2.75.2 - @agamedilab
XBB - @CorneliusRoemer
and the #LineageWatch team for 24/7 tracking & monitoring
cov-spectrum.org/collections/24…
BA.2.3.20 - @LongDesertTrain
BQ.1*/BQ.1.1* - @siamosolocani
BA.2.75.2 - @agamedilab
XBB - @CorneliusRoemer
and the #LineageWatch team for 24/7 tracking & monitoring
cov-spectrum.org/collections/24…
BA.2.3.20 [ ⛳️to track Convergent Mutations]
@PangoNetwork Proposal/Background
H/T @LongDesertTrain
github.com/cov-lineages/p…
@PangoNetwork Proposal/Background
H/T @LongDesertTrain
github.com/cov-lineages/p…
今週の国際製薬ニュース
色々ありましたが最後のオチはFDA
先にオチから。
現在オミクロン対応ワクチン！と各社が宣伝しているものは、中身は2020β株対応ワクチンであるのは指摘してきた通りです。
各社のHP見てください。よく見るとそう書いてたり、論文にはっきり書いてたり、開発記号に2020入って
色々ありましたが最後のオチはFDA
先にオチから。
現在オミクロン対応ワクチン！と各社が宣伝しているものは、中身は2020β株対応ワクチンであるのは指摘してきた通りです。
各社のHP見てください。よく見るとそう書いてたり、論文にはっきり書いてたり、開発記号に2020入って
たり
E484Kに対する抗体ができることが大事(従来株でできる抗体の効果にして約半分がここ)なので、β対応ワクチンでもある程度オミクロンへ交差すると分かってきたと。
そこへFDAがSTATEMENTを出しました。
ワクチン開発各社へ、「オミクロンBA1対応成分だけでなく、
fda.gov/news-events/pr…
E484Kに対する抗体ができることが大事(従来株でできる抗体の効果にして約半分がここ)なので、β対応ワクチンでもある程度オミクロンへ交差すると分かってきたと。
そこへFDAがSTATEMENTを出しました。
ワクチン開発各社へ、「オミクロンBA1対応成分だけでなく、
fda.gov/news-events/pr…
BA4/5対応成分も含めよ。二価ワクチンにしなさい。支援するよ」
は？そもそも今開発されている「対オミクロンワクチン」はβ対応ワクチンなんだが？
と最初思いましたが、ま、対応成分という言い方が妙で、要するにβ対応ワクチンでの交差期待はここに含まれるのでしょう。
は？そもそも今開発されている「対オミクロンワクチン」はβ対応ワクチンなんだが？
と最初思いましたが、ま、対応成分という言い方が妙で、要するにβ対応ワクチンでの交差期待はここに含まれるのでしょう。
New #PANGO designations - BA.2.*
BA.2.4Alias of B.1.1.529.2.4, #Singapore lineage
BA.2.5Alias of B.1.1.529.2.5, lineage in #Portugal and other countries
BA.2.6Alias of B.1.1.529.2.6, lineage in #France and other countries
BA.2.7Alias of B.1.1.529.2.7, #USA lineage
BA.2.4Alias of B.1.1.529.2.4, #Singapore lineage
BA.2.5Alias of B.1.1.529.2.5, lineage in #Portugal and other countries
BA.2.6Alias of B.1.1.529.2.6, lineage in #France and other countries
BA.2.7Alias of B.1.1.529.2.7, #USA lineage
These are new designations - branching from the BA.2 subvariant
more to follow ..... will update key mutational differences and transmission advantage (if any)
more to follow ..... will update key mutational differences and transmission advantage (if any)
BA.2.4 (aka B.1.1.529.2.4) | prevalent in Singapore
Key mutation: ORF6:M58K
COV-spectrum predicts a growth advantage of 14% over BA.2 and 46% over BA.1.1 in #Singapore
BA.2 and BA.1.1 are currently the dominant lineages in circulation in Singapore
Key mutation: ORF6:M58K
COV-spectrum predicts a growth advantage of 14% over BA.2 and 46% over BA.1.1 in #Singapore
BA.2 and BA.1.1 are currently the dominant lineages in circulation in Singapore
Recap settimanale su Covid: vediamo quello che è successo. Segue un thread con alcuni punti importanti, nel caso in cui ve li foste persi. Let's go!
1/n 🧵 #COVID19
1/n 🧵 #COVID19
Da una valutazione approfondita delle infezioni da BA.2 (>124.000 persone) vs BA.1 (>30.000) in Qatar sembrerebbe che BA.2 abbia cariche virali più elevate e periodi infettivi più lunghi. medrxiv.org/content/10.110… 2/n
Hong Kong ha i decessi pro capite più alti al mondo causa Covid e continua a crescere. Preoccupante. 3/n
3/n 
BA.2 is a sublineage of Omicron that's replacing the original BA.1 version in the U.S. I'll break down what we know about its effects on current antivirals and the facts behind #bebtelovimab, the newest anti-SARS-CoV-2 monoclonal antibody (mAb) that received FDA EUA. a🧵 1/
Compared to BA.1, BA.2 has quite a few changes to ORF1ab and the NTD region of Spike. Luckily, I don't see any mutations in nsp5 or 12 that would affect Paxlovid, remdesivir, or molnupiravir activity 2/
The other good news pertains to Evusheld (tix/cil). It took a hit vs BA.1/BA.1.1, but based on data from David Ho's group (biorxiv.org/content/10.110…), BA.2 has almost no effect on cilgavimab (CoV2-2130, blue box). This is great news for Evusheld and for our immunosuppressed pts 3/
